Spruce Biosciences (SPRB) Revenue (2023 - 2024)
Spruce Biosciences (SPRB) posted quarterly Revenue of $697000.0 for Q4 2024, down 75.97% year-over-year from $2.9 million in Q1 2024, and up 16.17% quarter-over-quarter from $600000.0 in Q3 2024.
Spruce Biosciences (SPRB) Revenue (2023 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported Revenue for 2 consecutive years, with $697000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Revenue fell 75.97% year-over-year to $697000.0; the TTM figure through Sep 2025 stood at $697000.0 (down 90.2% YoY), while the FY2024 annual figure was $4.9 million, down 51.38% from the prior year.
- Revenue climbed to $697000.0 in Q4 2024 per SPRB's latest filing, from $600000.0 in the prior quarter.
- Across five years, Revenue topped out at $3.1 million in Q3 2023 and bottomed at $600000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 697,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Sep 30, 2023 | 3.07 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 2.00 Mn |